ArticleThrombosis journal2013

Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model.

Léon Nshimyumukiza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.